Ipilimumab – Medxy AI

A nonrandomized trial reveals that combined nivolumab and ipilimumab treatment achieves a 54% response rate with durable effects in advanced ovarian and endometrial clear cell cancers, addressing critical unmet therapeutic needs.

Berberine Ursodeoxycholate (HTD1801): A Promising Oral Therapy for Type 2 Diabetes with Multifaceted Metabolic Benefits
HTD1801 Shows Promising Histologic Improvement in Metabolic Dysfunction-Associated Steatohepatitis: Insights from Preclinical and Phase 2 Clinical Studies
Berberine and Cinnamon Synergy: A Promising Adjunct Therapy for Improving Glycemic Control and LDL Cholesterol in Type 2 Diabetes
Preventive PCI for Vulnerable Non-Flow-Limiting Coronary Plaques in Diabetes: Insights from the PREVENT Trial
SADI-S vs RYGB for Obesity: Superior Weight Loss and Comparable Safety at 2 Years from the French SADISLEEVE Trial

About us
Contact us
MedXY story
Privacy Policy
Subscribe Now!
账号

English
日本語
Tiếng Việt
中文

AI artificial intelligence blood pressure breast cancer cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials COVID-19 diabetes diet dinh dưỡng exercise GLP-1 health heart failure HFpEF Hypertension immunotherapy inflammation longevity MASLD mental health Mortality NAFLD nutrition obesity Pregnancy prevention public health randomized controlled trial randomized trial sexual health sleep stroke sức khỏe sức khỏe tim mạch thử nghiệm lâm sàng treatment type 2 diabetes weight loss wellness women's health 臨床試験

Your health, we care

Scroll to Top